(Press-News.org)
The Response Evaluation Criteria In Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories (complete or partial response, or stable or progressive disease) based on the percent of change in the sum of the longest diameters of a set of target lesions.
An analysis of data from the SWOG S1609 trial conducted by the NCI-funded National Clinical Trials Network (NCTN) finds that in patients treated with immune checkpoint inhibitors, survival times correlate linearly with that change, rather than exhibiting threshold effects corresponding to those RECIST categories. This aligns with an earlier finding of a similar linear association with survival in patients treated with chemotherapy.
The results will be delivered in an oral presentation at the 2023 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago on June 4 by lead author Megan Othus, PhD, a biostatistician with the SWOG Statistics and Data Management Center and the Fred Hutchinson Cancer Center.
“I think that using just partial- and complete-response rate to define the ‘success’ of a trial can miss a signal,” Othus said, “because patients who haven’t achieved those levels of remission but also haven’t progressed do have an outcome that is associated with longer survival.”
Many early trials testing treatments in solid tumors rely on RECIST in measuring the effect the treatment has had on a patient’s cancer. At baseline, before a patient starts treatment, target lesions are identified – typically on CT or MRI scans – and their longest diameters are measured and totaled. This is the baseline value against which objective tumor response is evaluated.
In evaluating response from target lesions, the sum of these longest diameters must decrease by at least 30 percent for objective response to be categorized as a partial response. Tumor shrinkage by less than 30 percent is labeled stable disease.
To evaluate the association between quantitative change in RECIST tumor burden and patient overall survival and progression-free survival, Othus’s team analyzed data from 720 patients with a variety of rare cancers who were treated with checkpoint inhibitor therapy on the S1609 DART (Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors) clinical trial. DART was a federally funded basket trial that evaluated the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) in treating 53 cohorts of patients with rare tumor subtypes.
For the analysis presented at ASCO, the researchers looked at the percent change in the sum of the longest diameters of target lesions between each patient’s baseline assessment and their first scan after starting treatment. They used log-rank tests and Cox regression models to evaluate the association of those changes with patient overall survival and progression-free survival times.
Othus says the results are already having an impact on correlative work being done as part of the S1609 DART trial.
“We are using this finding to inform our translational medicine analyses,” she said. “This increases the number of patients we are defining as having a ‘good’ outcome, which gives us more power to evaluate potential biomarkers associated with outcomes.”
Study S1609 was funded by the NIH/NCI through grants U10CA180888 and U10CA180819, and was supported in part by Bristol Myers Squibb Company through a Cooperative Research and Development Agreement between the company and the NCI.
In addition to Othus, co-authors on the ASCO abstract included Sandip Pravin Patel, MD, of UC San Diego Moores Cancer Center; Young Kwang Chae, MD, MPH, of Northwestern University; Eliana Dietrich, of Fred Hutchinson Cancer Center; Howard Streicher, MD, and Elad Sharon, MD, MPH, both of Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute; and Razelle Kurzrock, MD, of Medical College of Wisconsin. The S1609 study team also includes Marcia Horn, JD, representing the voice of the patient in the development and conduct of the trial.
SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program and is part of the oldest and largest publicly funded cancer research network in the nation. SWOG has more than 18,000 members in 45 states and nine foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at swog.org, and follow us on Twitter at @SWOG.
Abstract Title: Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
Session Type/Title: Oral Abstract Session - Developmental Therapeutics—Immunotherapy
Session Date and Time: 6/4/2023, 9:45 AM-12:45 PM CT
https://meetings.asco.org/abstracts-presentations/222691
END
A new study from researchers in the Khurana lab at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, in close collaboration with researchers from the Ritz lab at UCLA and the Rubin lab at Harvard University, identified pesticides that could be relevant to the development of Parkinson’s disease. The study was led by Richard Krolewski, MD, PhD, a neurologist in the Brigham’s Division of Movement Disorders and Ann Romney Center for Neurologic Diseases, and Kimberly ...
Among patients with extensive stage small-cell lung cancer (SCLC) that is positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance atezolizumab immunotherapy plus the PARP inhibitor talazoparib had significantly longer progression-free survival (PFS) times than those who received atezolizumab alone (median PFS 4.2 months versus 2.8 months).
These results from the phase II S1929 trial conducted by the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), will be reported ...
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
The theme this year is Partnering With Patients: The Cornerstone of Cancer Care and Research. More than 30,000 people are expected to attend the meeting taking place in Chicago and online June 2-6, 2023.
“As the world’s leading clinical cancer meeting, ASCO is an important event for oncology professionals to share information on the latest ...
Multiple sclerosis has traditionally been considered a condition that predominantly affects white people of European ancestry. However, a new analysis conducted by a North American team led by University of Maryland School of Medicine (UMSOM) researchers suggests that the debilitating neurological condition is more prevalent in Black Americans than once thought. It is also far more prevalent in Northern regions of the country including New England, the Dakotas, and the Pacific Northwest.
Findings from the new study were recently published in the journal JAMA Neurology.
“We found a much higher prevalence of multiple sclerosis in Black Americans than previously ...
New results from a study led by USC researchers at Children’s Hospital Los Angeles show that a sensory adapted dental clinic environment creates less distressing oral care experiences for autistic children. The open-access article is available today in JAMA Network Open.
“We’ve shown that the combination of curated visual, auditory and tactile adaptations — all of which are easily implemented, relatively inexpensive and don’t require training to safely use — led to statistically significant decreases in autistic children’s behavioral ...
Key takeaways:
A UCLA study shows that a the outset of the COVID-19 pandemic, social interactions, both virtual and in person, declined significantly for married couples.
The decline was found to be greater and more long-lasting for Black and Latino couples and lower-income couples than for white couples and wealthier couples.
The researchers suggest exploring new ways of protecting public health during crises that also help more vulnerable populations sustain meaningful relationships.
Following the lockdowns and restrictions on public gatherings in the early days of COVID-19, the social networks of white, ...
Predicting a protein’s location within a cell can help researchers unlock a plethora of biological information that’s critical for developing future scientific discoveries related to drug development and treating diseases like epilepsy. That’s because proteins are the body’s “workhorses,” largely responsible for most cellular functions.
Recently, Dong Xu, Curators Distinguished Professor in the Department of Electrical Engineering and Computer Science at the University of Missouri, and colleagues updated their protein localization prediction model, MULocDeep, ...
Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by the activity of key cells and signaling pathways, a new study shows.
Led by researchers at NYU Grossman School of Medicine, the study mapped hidden features of inflammation and how they compared in cases of increasing severity of psoriatic disease. The team’s findings may help explain how small areas of skin inflammation can have wide-ranging effects in other parts of the body. Up to one-fifth of those with the skin disease, the researchers note, ...
-With pictures-
In a new study, bioscientists argue that strengthening the protection given to areas already protected under law or by local communities is as critical for safeguarding biodiversity as creating new protected areas.
The research team, which included scientists from Durham University, National University of Singapore (NUS) and Princeton University, found that about 70 per cent of the roughly 5000 species analysed either have no apparent representation in protected areas, occur in protected areas that have been downgraded, downsized or degazetted, ...
Researchers have for the first time characterised a unique molecular mechanism of the early stages of programmed cell death or apoptosis, a process which plays a crucial role in prevention of cancer.
The study, which is published today (Friday 2nd June 2023) in Science Advances, was led by Dr Luke Clifton at the STFC ISIS Neutron and Muon Source (ISIS) in Oxfordshire, alongside co-lead Professor Gerhard Gröbner at the University of Umeå and partners at the European Spallation Source in Sweden. It is ...
